Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune‐mediated inflammatory disorders?

@article{Chen2018DoTN,
  title={Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune‐mediated inflammatory disorders?},
  author={Yuehong Chen and Marcia A. Friedman and Gang Liu and Atul A Deodhar and Cong-Qiu Chu},
  journal={Cytokine},
  year={2018},
  volume={101},
  pages={78–88}
}
HighlightsTNFi are most commonly used in rheumatoid arthritis and inflammatory bowel diseases.TNFi is not associated with increased risks of overall cancer, lymphoma or melanoma.Inconsistent results among studies on risk in non‐melanoma skin cancer.Vigilance is advised in screening for risk factors for non‐melanoma skin cancer. ABSTRACT Inhibition of tumor necrosis factor (TNF) activity has profoundly changed the management of several immune‐mediated inflammatory diseases with great benefit for… Expand
Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis
TLDR
Exposition of anti-tumor necrosis factor alpha agents in patients with inflammatory bowel disease is not associated with a higher risk of lymphoma. Expand
Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology
TLDR
The role of TNF in graft-versus-host disease is discussed as an example of the ambivalence of this cytokine in the pathophysiology of an immunopathology, highlighting the therapeutic potential of triggering TNFR2 to boost Treg expansion. Expand
Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience
TLDR
The results of this study showed IR of malignancies in RMD patients treated with bDMARDs that is in agreement with literature data. Expand
Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data
TLDR
Analyses of the global postmarketing safety database and long-term clinical trial data showed no evidence of an increased risk of malignancy of any type following rituximab treatment in patients with RA. Expand
Association between inflammatory bowel disease and uveal melanoma: case report of two young adults and a literature review.
  • S. Cozzi, A. Escarpa, +5 authors C. Miguelez
  • Medicine
  • Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
  • 2019
TLDR
It seems reasonable to suggest that these two factors may have promoted the development of uveal melanoma, as both patients described in this report both had long-standing IBD treated with immunomodulatory drugs. Expand
Investigation of TNF-α and IL-6 Levels in the Sera of Non-Melanoma Skin Cancer Patients.
TLDR
The increased levels of TNF-α and IL-6 in NMSC patients can be introduced as an epiphenomenon of a complex cancer-induced cytokine cascade. Expand
Clinical context for cancer risk of immunosuppressive agents used in dermatology
TLDR
This article estimates the number of patients a provider would need to treat with a given agent in 1 year to cause a single adverse outcome over time and reviews available information on the risk of malignancies in patients treated with these agents. Expand
Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis
TLDR
Findings in this study provide new insights into the understanding of fexofenadine action and underlying mechanisms but also provide new therapeutic interventions for various TNF-α and cPLA2-associated pathologies and conditions, particularly inflammatory rheumatic diseases. Expand
Lymphoma Risk and Screening in IBD
TLDR
The role of Epstein-Barr virus in the development of lymphoma and the evolving understanding of the risk of hepatosplenic T-cell lymphoma (HSTCL) with IBD therapies are discussed. Expand
Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study.
TLDR
In this large cohort study from five Nordic countries, no increased risk of solid cancer in TNFi-treated PsA patients, neither for solid cancer overall nor for eight common cancer types. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 111 REFERENCES
Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.
TLDR
Short-term cancer risk was not elevated among patients treated with TNFα inhibitor therapy relative to commonly used therapies for immune- mediated chronic inflammatory diseases in this study. Expand
Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease.
TLDR
Exposure to TNF-α antagonists among patients with IBD was not associated with an increased risk of cancer over a median follow-up of 3.7 years among those exposed, and no site-specific cancers were in significant excess in fully adjusted models. Expand
Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy
TLDR
The results provide some reassurance of the safety of biologic treatments in the treatment of RA by assessing the incidence of serious infections leading to hospitalization and malignancies among patients with rheumatoid arthritis receiving either TNF inhibitor or rituximab (RTX) therapy. Expand
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden
TLDR
Overall, patients with rheumatoid arthritis who have not been treated with biological drugs are not at increased risk of invasive melanoma compared with the general population, and may not markedly shift the overall risk-benefit balance of TNF inhibitors as used in clinical practice. Expand
Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
TLDR
Current data are insufficient to establish a causal relationship between RA treatments and the development of lymphoma, although the SIR is greatest for anti-TNF therapies, differences between therapies are slight, and confidence intervals for treatment groups overlap. Expand
Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
TLDR
The addition of TNFi to sDMARD does not alter the risk of cancer in RA patients selected for TNFi in the UK, and there was no difference in the relative risk ofcancer for any of the individual TNFi drugs. Expand
The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study
TLDR
It is suggested that RA patients taking TNF-α antagonist are associated with a lower risk of cancer, but not for hematologic cancers, than RA patientsTaking nbDMARDs alone. Expand
Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
TLDR
Patients with rheumatoid arthritis or IBD who use methotrexate, anti-tumor necrosis factor (anti-TNF) therapy, or thiopurines after an initial NMSC are studied to determine the relative hazard of a second NMSCs. Expand
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
TLDR
Overall and as used in routine care against RA, TNF antagonists are not associated with any major further increase in the already elevated lymphoma occurrence in RA. Expand
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.
TLDR
Risk of lymphoma is substantially increased in a subset of patients with RA, those with very severe disease, and high inflammatory activity, rather than its treatment, is a major risk determinant. Expand
...
1
2
3
4
5
...